CLINICAL_TRIALS ClinicalTrials.gov record update

DiaPrecise, A Phase II Open Label Study to Evaluate the Safety and Feasibility of Intralymphatic Administration of Diamyd® in Individuals at Risk for Type 1 Diabetes Carrying the HLA DR3-DQ2 Haplotype

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05683990
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:29:07.248780+00:00
Published At: 2026-04-20T00:00:00+00:00
Record Updated At: 2026-04-20
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diabetes Mellitus, Type 1", "Autoimmune Diseases", "Prevention"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-04-20"
protocolSection.identificationModule.nctId: "NCT05683990"
protocolSection.identificationModule.officialTitle: "DiaPrecise, A Phase II Open Label Study to Evaluate the Safety and Feasibility of Intralymphatic Administration of Diamyd\u00ae in Individuals at Risk for Type 1 Diabetes Carrying the HLA DR3-DQ2 Haplotype"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.